Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPT-302 plus aflibercept versus aflibercept alone in neovascular age-related macular degeneration
NL-OMON59536Phase 3Completed
- Sponsor
- Opthea Limited
- Start
- Jan 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in exudative macular degeneration comparing OPT-302 + aflibercept with aflibercept alone (2 arms). Primary endpoint: Mean change from baseline to Week 52 in ETDRS best-corrected visual acuity letters. Started Jan 2022; status: completed.
02
Drugs
soziniberceptaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NL-OMON59536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59536.